Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

Ebola virus (EBOV) infections cause haemorrhagic fever, multi-organ failure and death, and survivors can experience neurological sequelae. Licensing of monoclonal antibodies targeting EBOV glycoprotein (EBOV-GP) improved its prognosis, however, this treatment is primarily effective during early stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ha-Na, McWilliams, Ian L., Lewkowicz, Aaron P., Engel, Kaliroi, Ireland, Derek D. C., Kelley-Baker, Logan, Thacker, Seth, Piccardo, Pedro, Manangeeswaran, Mohanraj, Verthelyi, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583756/
https://www.ncbi.nlm.nih.gov/pubmed/34674613
http://dx.doi.org/10.1080/22221751.2021.1997075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583756/
https://www.ncbi.nlm.nih.gov/pubmed/34674613
http://dx.doi.org/10.1080/22221751.2021.1997075

Ejemplares similares